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Abstract
Small bowel cancer is one of the rarest can-
cers in the gastrointestinal tract. The diagno-
sis is usually late and most patients presented
with the advanced stage. Because of this rarity,
there is limited data when making decisions
for treatment and biological behavior. Most
forms of the cancer occur in the duodenum
with surgery being the treatment of choice if
the cancer is operable. Chemotherapy has an
accepted role in duodenal cancer, with the best
form being regimen, which yields the best
result in combination with capecitabin and
oxaliplatin. Our case patient was present with
liver metastasis and a huge mass in her first
duodenal region so we were required to use
chemotherapy and radiotherapy. Like other
duodenal cancers, the metastasis decreased
her survival and she died about 13 months
after diagnosis.
Introduction
Small bowel cancer is one of the rarest can-
cers in the gastrointestinal (GI) tract. It com-
prises of about 70-80% of length and about 90%
of the surface area of the alimentary tract.
Incidences of small intestine cancers are 40-50
fold lower than that of colon cancers,1 overall
accounting for 1% of GI cancers,2 with half of
them occurring in the duodenum.3 It seems
that duodenal cancer has the worst prognosis
than other small bowel carcinoma. Small intes-
tine cancers comprise of 44% carcinoid, 33%
adenocarcinoma, 15% lymphoma, and 3 cases
of squamous cell carcinoma (SCC) reported.4
About 45% of these cancers occurred in the 3rd
and 4th portion of the small intestine,3 most of
them being sporadic. The most common site of
metastasis are the regional lymph nodes, the
liver, and the lungs.5
There are a variety of diagnostic procedures
used including barium study, computed tomog-
raphy (CT) scan, magnetic resonance imag-
ing, entroclysis, entroscopy and endosonogra-
phy.6-13 Because of a lack of specific symptoms,
the diagnosis is usually made late and as a
result the overall survival is about 15 months
in metastatic patients.14-21 Definitive surgery is
the best way to cure. Radical pancreaticodu-
denectomy (Whipples) operation is the best
surgery for the cancers of the first and second
parts of the duodenum. There is not any data
present to support the benefits of adjuvant
treatment after curative surgery,1 but
chemotherapy has an accepted role in the
treatment of small intestinal cancers.22-24 The
mainstay of chemotherapy regimens are based
on SFU.25 SFU combined with platinum is more
effective than SFU alone,26-29 and in some stud-
ies, SFU combined with irinotecan or gemc-
itabine has been useful as well.16 The best
chemotherapy regimen with a 60% response
rate and 20% survival rate, however, is a com-
bination of capecitabine and oxaliplation
(XELOX).30 Due to the rarity of these tumors,
information about their biology and treatment
of this cancer have not yet been completed.31,32
The median overall survival in these
patients with metastatic disease was reported
at 15 months with a highly active combination
of cabcitabine and oxaliplatine. In this article,
we reported a case with huge duodenal adeno-
carcinoma mass with liver metastasis at diag-
nose. 
Case Report
The patient was a 41 years old, non-smoking
female who suffered from chronic dyespia,
recently complaining of weight loss, nausea,
and vomiting. In the physical exam, however,
there were no other signs and symptoms rec-
ognized except for weight loss. Upper GI
endoscopy was done and there was a huge
necrotic mass in the first duodenal section
which had obliterated the lumen. A biopsy was
taken and the result was a poorly differentiat-
ed adenocarcinoma with vascular invasion. A
CT scan revealed that there was a mass meas-
uring 10.12 cm and multiple liver metastasis
yet lab tests showed that renal and liver func-
tions were normal: carcinoembryonic antigen
(CEA)=0.34 and hemoglobin=8.5. Because of
the liver metastasis, neoadjuvant chemothera-
py was done with capecitabine and oxaliplatin
and we decided to refer her to surgery if the
response to chemotherapy was good. After 4
courses of chemotherapy, we evaluated her
with a CT scan with the results showing that
the size of the duodenal mass and liver metas-
tasis had increased (12.12) yet chest CT scans
and lab tests were normal (CEA=1.46). Due to
pain, mass effect, and no response to
chemotherapy, we started radiation therapy
(RT) with a local field with a total dose of 45 Gy
in 25 fractions and there was quickly a dramat-
ic response to radiation therapy. We have CT
before and after RT (Figure 1A). Once the pain
subsided, we started chemotherapy again with
capecitabine and irinotecan and over a 4
course, the mass size was 4.4 cm and the liver
metastasis had become smaller (Figure 1B).
We referred her for radiofrequency ablation for
the liver metastasis and then to the surgery
department. Radiofrequency was done but yet
the patient was inoperable so we continued
chemotherapy with capecitabine and irinote-
can for another 2 courses. After seven months
of radiation therapy, ascites and peritoneal
seeding were happening so we did palliative
care for her. Because lab tests were normal
and the patient could tolerate further treat-
ment, she received chemotherapy with
Gemcitabine along with D1 and D8 every 3
weeks until she died 13 months after the first
diagnose.
Discussion and Conclusions
Like other cases of small bowel cancers, in
our case, lack of specific symptoms, made the
diagnose late. Because she had liver metasta-
sis and a large mass, the diagnose was not dif-
ficult. We used CT scan and endoscopy for
diagnoses. Most small intestine cancers occur
in the 3rd and 4th portions of the duodenum, but
in this case, it was in the first duodenal por-
tion. according to previous studies mentioned
XELOX as the best regimen for this cancer we
started it, but the mass size and liver metasta-
sis increased. We try Capecitabin and irinote-
can, it was the best combination in our case.
Although the role of neoadjuvant radiation was
not well established because of mass effect we
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had to use it, and the response was deramatic.
In multivariate analysis advance stage, poor
histological pathology, age and duodenal pri-
mary are associated with poor prognosis
according to some studies presence of vascular
invasion is another factor for poor prognosis.
In our case  we had vascular invasion, poorly
differentiated and duodenal origin. The medi-
an survival in patients with metastasis report-
ed 15 months with XELOX. Our patient was
alive for 13 months but the best regimen used
in this case was capecitabin and irinotecan.
Due to the rarity of this tumor, there is not any
consensus about treatment. It seems that
according to each case we can use  surgery,
chemotherapy and radiation therapy.
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Figure 1. Computed tomography images before (A) and after (B) radiation therapy show
the reduction of the liver metastasis.
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